Drug Type Antibody drug conjugate (ADC) |
Synonyms Zalontamab brengitecan, BL B01D1, BL-B01D1 + [1] |
Mechanism DNA topoisomerase inhibitors, EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | CN | 22 May 2024 | |
Triple Negative Breast Cancer | Phase 3 | CN | 01 May 2024 | |
Hormone receptor positive breast cancer | Phase 3 | CN | 24 Apr 2024 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | CN | 24 Apr 2024 | |
Esophageal Squamous Cell Carcinoma | Phase 3 | CN | 19 Mar 2024 | |
Nasopharyngeal Carcinoma | Phase 3 | CN | 04 Dec 2023 | |
HER2-negative breast cancer | Phase 2 | CN | 12 Dec 2023 | |
Transitional Cell Carcinoma | Phase 2 | CN | 11 Dec 2023 | |
Colorectal Cancer | Phase 2 | CN | 16 Nov 2023 | |
Stomach Cancer | Phase 2 | CN | 16 Nov 2023 |
NCT05470348 (PRNewswire) Manual | Phase 1 | 127 | BL-B01D1 | atesngmilr(fxjeldxfjn) = aujpluevmk rrltcqcfmg (msoigjelwi ) View more | Positive | 05 Dec 2023 | |
NCT05194982 (ESMO2023) Manual | Phase 1 | 114 | jpcgdvxxdt(bychlutvhw) = pfiwpsnixx lgbftagpzf (rhuxrzjwqn ) | Positive | 21 Oct 2023 | ||
(EGFRmut) | rudmlyfkxc(igbgqtitmq) = rmlnejmhlw vrluqxwpwn (zgllglthyn, 75.2-97.1) View more | ||||||
NCT05194982 (ASCO2023) Manual | Phase 1 | 120 | (EGFRmut + NSCLC) | gsnisimmut(qtrtizwgpb) = neutropenia, febrile neutropenia and thrombocytopenia at 3.0mg/kg QW and 3.5mg/kg D1D8 Q3W xaanctcuyv (zivuibjjzv ) View more | Positive | 31 May 2023 | |
(EGFRwt + NSCLC) |